Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTFatima GulzarSat, June 27, 2026 at 5:31 PM GMT+2 1 min readNeuroPace, Inc. (NASDAQ:NPCE) is one of the 10 Best Brain-Computer Interface Stocks to Buy.On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data.Built on 124,450 epileptologist-labeled records, the company reported that the tool has "ECoGs of Interest." It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions.Chief Medical Officer Martha Morrell said the feature "represents an important advancement," with faster access to insights for more informed care.NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ Image Point Fr/Shutterstock.comCEO Joel Becker said the approval shows how the firm's data advantage is moving toward "practical tools for clinicians."NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026.NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat epilepsy and neurological illnesses. It offers implantable components such as the RNS neurostimulator and depth and cortical strip leads.While we acknowledge the potential of NPCE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.Disclosure: None. Follow Insider Monkey on Google News.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info